Artwork

Kandungan disediakan oleh Small Caps. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Small Caps atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Player FM - Aplikasi Podcast
Pergi ke luar talian dengan aplikasi Player FM !

Imugene (ASX: IMU) steps up dosage at groundbreaking VAXINIA cancer trial (w/ Leslie Chong)

19:18
 
Kongsi
 

Manage episode 398070393 series 2701497
Kandungan disediakan oleh Small Caps. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Small Caps atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

Imugene (ASX: IMU) chief executive officer and managing director Leslie Chong joins Small Caps to discuss the progress of the company’s phase 1 MAST trial of its novel cancer-killing virus CF33-hNIS – known as VAXINIA.

The oncolytic virus in VAXINIA has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models. After obtaining promising early results from trials,

Imugene is now increasing its dosage rates for a trial which is combing VAXINIA with pembrolizumab.

Imugene recently reported that 38 patients had been dosed with VAXINIA during the continuing dose escalation phase.

Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in the United States and Australia.

Articles:
https://smallcaps.com.au/imugene-novel-cancer-treatment-enters-new-phase-mast-trial/
https://smallcaps.com.au/imugene-positive-outcomes-novel-virus-trial-advanced-cancers/

For more information on Imugene:
https://smallcaps.com.au/stocks/asx-imu/

See omnystudio.com/listener for privacy information.

  continue reading

129 episod

Artwork
iconKongsi
 
Manage episode 398070393 series 2701497
Kandungan disediakan oleh Small Caps. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Small Caps atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

Imugene (ASX: IMU) chief executive officer and managing director Leslie Chong joins Small Caps to discuss the progress of the company’s phase 1 MAST trial of its novel cancer-killing virus CF33-hNIS – known as VAXINIA.

The oncolytic virus in VAXINIA has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumours in preclinical laboratory and animal models. After obtaining promising early results from trials,

Imugene is now increasing its dosage rates for a trial which is combing VAXINIA with pembrolizumab.

Imugene recently reported that 38 patients had been dosed with VAXINIA during the continuing dose escalation phase.

Overall, the study aims to recruit up to 100 patients across approximately 10 trial sites in the United States and Australia.

Articles:
https://smallcaps.com.au/imugene-novel-cancer-treatment-enters-new-phase-mast-trial/
https://smallcaps.com.au/imugene-positive-outcomes-novel-virus-trial-advanced-cancers/

For more information on Imugene:
https://smallcaps.com.au/stocks/asx-imu/

See omnystudio.com/listener for privacy information.

  continue reading

129 episod

Alle afleveringen

×
 
Loading …

Selamat datang ke Player FM

Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.

 

Panduan Rujukan Pantas

Podcast Teratas